Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Metsera, Inc.

$70.5

-0.24 (-0.34%)

C 41Pipeline Score Overvalued Pharma · Clinical
Market Cap
7.43 B
EPS
-2.99
P/E Ratio
-
Value Trade
1.96 B
-8.97 %
Week
34.06 %
1 Month
127.42 %
3 Month
174.75 %
6 Month
176.47 %
5 Year
176.47 %
All Time
Cash Data

  • Cash Position

    12.35 K

  • Monthly Burn

    12.35 K

  • Runway

    12,345 mo

Overview
Volume
27.91 M
52 Week Range
12.30 - 83.86
% held by Insiders
51.74 %
% held by Institutions
38.8 %
Enterprise Value
6.98 B
Total Shares
105.06 M
Short %
10.36 %
Float Shares
46.05 M
Company Description
Founded:2025

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C41
Pipeline Score
$2.0B
Pipeline Value
Overvalued
Valuation Signal
2
Drugs Scored
0.3x
rNPV / MCap
Top 60%
Small Cap
(rank 363 of 905)
Percentile Rank
Metsera, Inc. carries a moderate pipeline score (41/100), with $3.1B risk-adjusted pipeline value, led by MET097 in Obesity and Overweight (Phase 3).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
MET097
Monoclonal antibody		Obesity and OverweightPhase 3NCT0685761761% $2.4B COMPLETED 3,621 - -Mar 15, 2025 -Jan 28, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
MET-233i
obesity,metabolic diseases
Phase 1
2025-07-29
MET-233i
obesity,metabolic diseases
Phase 1
2025-07-29
MET-233i
obesity,metabolic diseases
Phase 1
2025-07-29
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in MTSR
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Metsera, Inc. (MTSR) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
MTSR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MTSR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MTSR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
MTSR Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
MTSR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How MTSR ranks across every disease it competes in
Competitive Position is a premium feature
See how MTSR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial